Methyl 2-chloropyrimidine-5-carboxylate: A Vital Fine Chemical Intermediate
Discover the synthesis, applications, and quality of this key pharmaceutical building block.
Get a Quote & SampleProduct Core Value
Methyl 2-chloropyrimidine-5-carboxylate
This compound serves as a crucial intermediate in the synthesis of ACSS2 inhibitors, which exhibit significant anti-inflammatory and anti-depressant activities. Its precise chemical structure and high purity make it invaluable for advanced pharmaceutical research and development.
- Unlock potential therapeutic benefits by utilizing methyl 2-chloropyrimidine-5-carboxylate synthesis for novel drug candidates.
- Reliable methyl 2-chloropyrimidine-5-carboxylate suppliers ensure consistent quality for your research and production needs.
- Explore the detailed 287714-35-6 chemical properties to optimize your synthetic pathways.
- As a critical component in fine chemical synthesis building blocks, it supports innovation in medicinal chemistry.
Advantages Offered
Purity and Quality
Ensuring high purity through rigorous quality control is essential for achieving reliable outcomes in ACSS2 inhibitor synthesis.
Versatile Intermediate
The compound's structure makes it a versatile building block for creating a wide array of complex molecules in pharmaceutical intermediate applications.
Research and Development Support
Accessing high-quality methyl 2-chloropyrimidine-5-carboxylate is fundamental for accelerating drug discovery and development processes.
Key Applications
Pharmaceutical Synthesis
Used in the preparation of complex molecules for potential therapeutic agents, demonstrating its role in buy methyl 2-chloropyrimidine-5-carboxylate for medicinal purposes.
Chemical Research
Valuable for laboratory research, enabling scientists to explore new reaction pathways and develop novel compounds.
Drug Discovery
A key component in the development of new drugs, particularly those targeting inflammation and depression.
Medicinal Chemistry
Essential for chemists working on structure-activity relationships and designing new pharmaceutical entities.